JONES FINANCIAL COMPANIES LLLP
Position in FENC — Fennec Pharmaceuticals Inc.
CIK 815917
DES PERES, MO
Position in FENC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$280,059
+$126,605 QoQ
Shares Held
26,052
+4.4% QoQ
Ownership
0.074%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#48
of 104 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in FENC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JONES FINANCIAL COMPANIES LLLP holds $339,789,023 across 287 Biotechnology names. FENC ranks #54 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
215,419 | $107,005,079 | |
| 2 | TECH |
BIO-TECHNE Corp
|
797,001 | $56,308,120 | |
| 3 | SLS |
SELLAS Life Sciences Group, Inc.
|
2,304,561 | $34,015,320 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
80,491 | $24,230,204 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
28,691 | $17,889,985 | |
| 6 | ARGX |
Argenx SE
|
14,657 | $13,598,324 | |
| 7 | ARDX |
Ardelyx, Inc.
|
1,765,932 | $9,006,253 | |
| 8 | INSM |
INSMED Inc
|
68,803 | $7,335,774 |
All Filings in FENC
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $280,059 | 26,052 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $153,454 | 24,952 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $192,130 | 24,952 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $87,984 | 9,400 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $79,265 | 9,550 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $53,896 | 8,850 | Shares | Sole | 2025-05-28 | |
| 2024-12-31 | $43,924 | 6,950 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $28,750 | 5,750 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $3,971 | 650 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||